Skip to content
Medical Health Aged Care

QPS Launches New Leukopak and Cell Therapy Products Facility

QPS Holdings, LLC 3 mins read

Clinical Research Supports Economic Growth and Development, While Making a Global Difference


SPRINGFIELD, Mo.--BUSINESS WIRE--

QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. QPS is a full service CRO that’s dedicated to supporting drug development from conceptualization through to commercial launch. This facility is providing critical raw materials for the research and development of cell therapies but will soon be supporting clinical and commercial cell therapy companies and patients. In addition, this new facility will support the local economy by providing stipends to blood product donors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113328476/en/

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

To build out the facility and ensure the success of this new venture, QPS has hired Tia Hexom, PhD, (Senior Director of Cell Therapy Services and Manufacturing). With over a decade of experience in the cell therapy field, Hexom is excited to be building cell therapy capabilities in the Midwestern United States.

QPS Missouri is a division of QPS Holdings LLC, a global Clinical Research Organization (CRO) that conducts studies on behalf of pharmaceutical and biotech companies for the development of new and existing pharmaceutical products. This new Leukopak and Cell Therapy products donation and processing center will be housed in the same building as the new, state-of-the-art Screening and Recruitment Center that opened in July 2022, located at 2025 W. Sunshine Street, Springfield, MO. Study participants and blood product donors are paid a stipend for their participation in these Clinical Research activities. These stipends benefit the study participants and donors and, therefore, the local economy.

“Our participants and donors are a key part of the success of QPS in Springfield, Missouri and they continue to make a difference by helping advance drug development research,” states Brendon Bourg, Vice President, Early Phase Clinical/Head of Administration QPS Missouri. “To have the opportunity and ability to provide this type of supplemental income to our local community, while providing a valuable service to our pharmaceutical and biotech clients is something we (QPS) are honored to be a part of.”

Located in Springfield, QPS Missouri has been conducting clinical research studies for over 30 years, with the help of more than 50,000 study participants. In addition to the new Cell Therapy facilities, the Springfield campus houses five independent clinics with more than 240 beds, a pharmacy with a retention area, local and central CAP/CLIA safety lab, a clinical trial kit processing area, and a 2,500 square foot negative pressure room.

QPS has always been on the front line of clinical research in all areas of pharmaceutical and biotech drug development. Since opening its doors in Springfield in 1994, QPS Missouri has conducted more than 2,000 Phase I FDA-regulated studies and paid over $50 million to local participants and donors.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products (such as Leukopaks and PBMCs), clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I clinical facilities, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.


Contact details:

Gabrielle Pastore, QPS Marketing
Phone: 302-287-7821
Email: gabrielle.pastore@qps.com
Website: www.qps.com

Media

More from this category

  • Medical Health Aged Care
  • 14/11/2024
  • 10:57
DEBx Medical B.V.

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

Propelling the Next Phase of Innovation in Chronic Wound ManagementDEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare.AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 (GLOBE NEWSWIRE) -- DEBx Medical, an Amsterdam-based pioneering innovator in the field of advanced wound care, announces the successful completion of its second capital investment round led by TVM Capital Healthcare. The funding will accelerate DEBx Medical’s global expansion into major markets around the world.The investment follows a successful initial round of funding and reflects growing confidence in DEBx Medical’s innovative…

  • Medical Health Aged Care
  • 14/11/2024
  • 10:55
Novotech

Novotech Releases In-Depth Report on Cervical Cancer: Addressing a Global Health Challenge

BOSTON–BUSINESS WIRE– Novotech, the global full-service clinical Contract Research Organization (CRO), has released a new report, Cervical Cancer – Global Clinical Trial Landscape. This…

  • Contains:
  • Medical Health Aged Care
  • 14/11/2024
  • 10:42
GSK Australia

Australian scientist recognised for decades of groundbreaking brain disease research

Professor Matthew Kiernan has won the 2024 GSK Award for Research Excellence for his groundbreaking research into neurodegenerative diseases, including motor neurone disease and frontotemporal dementia.1 His discoveries have led to new diagnostic criteria for neurodegenerative diseases – now used globally by the World Federation of Neurology. Professor Kiernan’s research has paved the way for clinical trials of new innovative therapies in Australia and globally. The GSK Award for Research Excellence is one of Australia’s most prestigious and longstanding medical research awards. Professor Matthew Kiernan – Chief Executive Officer and Institute Director at Neuroscience Research Australia (NEURA) and Scientia Professor…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.